Analysts Offer Predictions for CRSP FY2024 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Brookline Capital Management lowered their FY2024 earnings estimates for CRISPR Therapeutics in a note issued to investors on Tuesday, November 5th. Brookline Capital Management analyst L. Cann now forecasts that the company will post earnings per share of ($5.18) for the year, down from their prior estimate of ($4.88). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.47) per share. Brookline Capital Management also issued estimates for CRISPR Therapeutics’ Q4 2024 earnings at ($1.36) EPS, FY2025 earnings at ($5.76) EPS, FY2026 earnings at $8.07 EPS, FY2027 earnings at $11.96 EPS and FY2028 earnings at $26.00 EPS.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.41. The business had revenue of $0.60 million during the quarter, compared to analysts’ expectations of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same period in the prior year, the company earned ($1.41) earnings per share.

Other equities analysts also recently issued research reports about the stock. Needham & Company LLC restated a “buy” rating and set a $84.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday. Royal Bank of Canada reiterated a “sector perform” rating and set a $53.00 target price on shares of CRISPR Therapeutics in a research report on Wednesday. Cantor Fitzgerald restated a “neutral” rating on shares of CRISPR Therapeutics in a research report on Thursday, August 8th. Stifel Nicolaus reduced their price objective on shares of CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating for the company in a research note on Tuesday, August 6th. Finally, Truist Financial dropped their target price on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a report on Monday, August 12th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $74.94.

CRISPR Therapeutics Trading Down 0.5 %

Shares of CRSP stock opened at $51.62 on Friday. CRISPR Therapeutics has a twelve month low of $43.42 and a twelve month high of $91.10. The business’s 50 day moving average is $47.45 and its two-hundred day moving average is $52.18. The company has a market capitalization of $4.41 billion, a P/E ratio of -18.24 and a beta of 1.67.

Institutional Trading of CRISPR Therapeutics

Several institutional investors have recently added to or reduced their stakes in CRSP. Capital International Investors lifted its stake in CRISPR Therapeutics by 27.8% during the first quarter. Capital International Investors now owns 7,837,074 shares of the company’s stock worth $534,175,000 after purchasing an additional 1,702,624 shares during the last quarter. SR One Capital Management LP bought a new position in CRISPR Therapeutics in the 1st quarter worth approximately $71,496,000. Farallon Capital Management LLC bought a new stake in CRISPR Therapeutics during the 2nd quarter valued at $28,625,000. Avoro Capital Advisors LLC acquired a new position in CRISPR Therapeutics during the 1st quarter worth $28,599,000. Finally, Marshall Wace LLP acquired a new position in shares of CRISPR Therapeutics during the second quarter valued at $10,078,000. 69.20% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 4,293 shares of the company’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $198,680.04. Following the completion of the sale, the chief executive officer now directly owns 226,540 shares in the company, valued at $10,484,271.20. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 4,293 shares of the firm’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $198,680.04. Following the transaction, the chief executive officer now directly owns 226,540 shares of the company’s stock, valued at $10,484,271.20. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, General Counsel James R. Kasinger sold 1,089 shares of the company’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $50,398.92. Following the completion of the transaction, the general counsel now owns 62,597 shares of the company’s stock, valued at approximately $2,896,989.16. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.